Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, that's a first...I actually agreed with you on a post...LOL
OK, I am having a brain fart over here...what is an RM?
better than a "screw you all the way to montana" split...LOL..that means the doors are open
well,
against my better judgment, I called the company...spoke with Cindy E. With as little as she can say legally, she said she is severely optimistic that the doors will remain open...
She was not at liberty to say why Malcolm resigned...no need to state the obvious I guess...
now the ultimate gamble...wait or not...
Thank you
no reason to be cruel...
yeah, it can't get any worse...I should have shut my mouth..
what? could you repeat that middle part? I didn't get it...
whatcha say? I guess I am getting old, could you please repost, over and over and over again? maybe it will sink in...
then again, i have much better things to do with my time...
arnold...kindly refresh my memory. When I have defended him in the recent past?
thanks and have a great weekend
yap yap yap...
Conrad was a swindler...
Yin is a swindler...
Cy Stein is a swindler...
etc...all I see are swindlers...
get over it...
is said the technology was sound...not the company/management...
now don't be stupid...
dude,
lazarus is a nut...
CYGX technology is not...
jeeze...
has anyone heard anything? This is anemic....
um...Paulness, I am a true shareholder, still, and have no idea what was said...
don't know...how quickly can wunderlich and vasquez buy their shares at 5 cent?
I will..no increase in share price...darn it....
So I take it nobody went to the shareholder's meeting?
or some people did and don't want to admit holding shares?
I am a holder...and did not go...and before everyone goes crazy asking me why I hold...it is my right to....and I don't need to sell them...
no, that is not true...if it were in a plane, it would have gone up...LOL
Pumper!!!!!!!!!!!!!!!!!!
LOL
ok, ok...I'm here too, haven't sold in the past 2 years...sold enough over a dollar not to worry with this..I haven't lost the faith...but sometimes I am pushed a little...
no, the old numbers were 19%, now up to 25%
even worse...1 in 4 have genital herpes...most everyone has some type of herpes...and yes...it can be latent for a looooooooooooooooooong time...kind of like this company LOLOLOLOLOL
Now you get the point...would you like to buy some shares? LOL
ISIS was the market leader when CYGX started...if CYGX started at the same time, ISIS would still probably be the leader...LOL
would you mind telling me how long it took Imclone (no insider trading fiasco included) to get something to market?
Yes I believe the board surely understands the science more than you, and probably the business more than us...
but then again it is only my opinion...
if they didn't think the shares were worth (or will be worth) anything, the would not be on the board...why waste their time?
LOL...maybe we need a booster....
ummm...no, it protected against a lethal dose of virus...
has anyone dropped by the CYGX offices....are they still there? I emailed the company through the shareholder update email, and no response....
sorry, but a double negative means a positive, so it would have amounted to something...LOL
I feel good today, might be the 80 degree weather and sun in Philly, but what would make my year is a PR today saying either 1)New CEO or 2)financing is actually here or 3) Simplivir was just bought by Merck
hey my birthday was Tuesday, I can dream can't I?
CytoGenix Announces Results of Simplivir™ CY301 Herpes Cream Pre-Clinical Animal Study
Houston, TX, (March 2, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announced today that a pre-clinical animal study has demonstrated that Simplivir™ (CY301) reduced the size of herpes lesions compared to placebo. In this study, Simplivir™ was applied to herpes infected skin of guinea pigs twice daily for three days.
The treatment with 0.1% Simplivir™ resulted in a reduction in the total lesion area when compared to placebo. A trend toward a reduction in the amount of herpes virus was observed as well. Simplivir™ activity in this pilot study is encouraging and additional studies to optimize the dose and timing of therapy will follow.
Herpes is a public health problem of major significance in the United States and worldwide. The Centers for Disease Control and Prevention has reported that 45 million people ages twelve and over test positive for the type of herpes most often affecting the genital area. Active lesions from herpes infections can have catastrophic effects on newborn children and are a major risk factor for the transmission of other diseases such as AIDS.
Dr. Malcolm Skolnick, CytoGenix President and CEO, commented, "This is the first in a series of in-life proof-of-principle data we expected based on our earlier observations in cell culture where Simplivir™ reduced viral titer load up to 500-fold. These data extend the validation of CytoGenix' proprietary delivery method for topical administration of plasmid DNA-based therapeutics."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (407) 774-9949
I distinctly recall these lines....
100% that got simplvir (maybe it wasn't called simplivir, but it was their anti-herpes product)lived, 100% that did not died....
folks?
if you count Hogger...HAHAHAHA just kidding...
I think it was, they met with the FDA to see what else needed to be done...was that Simplivir?
how is that for a vote of confidence....someone is spending the big bucks for 200 and 250 shares....
sorry, I don't have time to read the report..what section has the GE issue in it?
TIA
10 cents would be nice today
last half hour could be interesting
besides the spelling..that would be accurate...LOL